Business Context and Reporting Period
This Form 8-K is filed by Cara Therapeutics, Inc. (not Tvardi Therapeutics, Inc., despite the metadata request) on January 14, 2025. The filing addresses the Company's status regarding Nasdaq listing compliance and a proposed merger with Tvardi Therapeutics, Inc.
Key Financial Metrics and Listing Status
- Stockholders' Equity: Reported at $707,000 as of September 30, 2024, which is below the Nasdaq Capital Market minimum requirement of $2.5 million.
- Minimum Bid Price: The Company regained compliance with the $1.00 minimum closing bid price requirement on January 16, 2025, following a one-for-twelve reverse stock split effective December 31, 2024.
- Listing Status: The Company's common stock trades on the Nasdaq Capital Market (transferred from Nasdaq Global Market on August 1, 2024).
Material Changes and Events
- Regained Bid Price Compliance: After a 180-day extension period, the Company satisfied the minimum bid price requirement for ten consecutive business days.
- Reverse Stock Split: A 1-for-12 reverse stock split was approved by the board on December 19, 2024, and implemented on December 31, 2024.
- Equity Non-Compliance Extension: Nasdaq granted an extension until May 19, 2025, to regain compliance with the stockholders' equity requirement.
- Proposed Merger: The Company is pursuing a merger with Tvardi Therapeutics, Inc., which is expected to constitute a "change of control" and require the combined entity to meet initial listing criteria.
Outlook, Risks, and Management Commentary
- Compliance Plan: The Company's plan to regain equity compliance relies on the closing of the proposed merger with Tvardi.
- Delisting Risk: There is no assurance the Company will regain compliance by the May 19, 2025 deadline. Failure to do so could result in delisting.
- Appeal Process: If delisting is initiated, the Company may appeal to a Nasdaq Hearings Panel, though success is not guaranteed.
- Forward-Looking Statements: The filing includes standard disclaimers regarding the uncertainty of the merger timeline and the ability to maintain listing status.
Investor Verification Checklist
- Verify the status of the proposed merger with Tvardi Therapeutics, Inc. and the likelihood of closing by May 19, 2025.
- Review the Form S-4 registration statement and preliminary proxy statement for details on the transaction and management interests.
- Monitor the Company's stock price to ensure it remains above the $1.00 minimum bid price post-split.
- Confirm the combined company's projected stockholders' equity to ensure it meets the $2.5 million threshold upon merger completion.